Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance

“…24 One observation study concluded that PSA DT correlated with disease progression. 25 However, these studies had short follow up and were unable to M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 12 determine the correlation with cancer metastasis or progression. PSA kinetics lack specificity due to the confounding effects of PSA lability and inflammation causing a sharp rise in PSA.…”

Eligibility for Active Surveillance and Pathological Outcomes for Men Undergoing Radical Prostatectomy in a Large, Community Based Cohort

“…2,3 Triggers for definitive therapy that vary by protocol and by individual include PSA doubling time less than 3 years, 16 grade progression on repeat biopsy 4 and stage progression on digital rectal examination. 17 However, in men with low risk disease an initial delay in therapy was reported to have minimal impact on curability 18 or the risk of biochemical progression. 19 Of the more than 1,300 men currently enrolled in published AS cohorts 8 only 2 were reported to have died of prostate cancer, of whom each underwent early therapy with PSA kinetics, suggestive of aggressive disease.…”

Active surveillance for the management of localized prostate cancer: Guideline recommendations

“…[5][6][7][8][9][12][13][14][15][16][18][19][20][21][22]29,32,33 The studies reporting their active surveillance protocol conducted multicore (6-to 17-core) biopsies every 1 to 2 years. 5,10,12,[15][16][17][18]21,23,[28][29][30][33][34][35] Five studies conducted multicore biopsies every 2 to 4 years. 8,11,13,19,32 Regarding Multiparametric MRI, it has been shown to be a good predictor of disease reclassification.…”